BioSpace News Archive

Vir Biotechnology, Inc. announced new data from its robust hepatitis B and D virus portfolio that were presented at the EASL™ Congress.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence of benefit on weight beyond treatment.

Sun Pharmaceutical Industries Ltd. announced results from two Phase 1 studies evaluating the tolerability, safety, pharmacokinetics and pharmacodynamics of GL0034, a novel long-acting GLP-1 receptor agonist, in non-obese and obese adults without diabetes.

Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company’s tirzepatide for chronic weight management in participants with obesity or overweighti and type 2 diabetes, showed that tirzepatide led to superior weight reduction versus placebo for both doses.

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that results from a Phase 1a clinical trial of ZP8396, the company’s long-acting amylin analog, will be presented during a late-breaking poster session at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S. Topline results from the trial were previously announced in March 2023.

Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented at the 83rd Scientific Sessions of the American Diabetes Association® in San Diego, CA.